Olema Pharmaceuticals, Inc. OLMA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$185.15M-43.6% | -$162.45M-25.5% | -$149.96M-22.2% | -$142.3M-29.8% | -$128.89M-29.8% | ||
| $481K+11.1% | $490K+24.7% | $419K+14.8% | $471K+30.8% | $433K+18.6% | ||
| $23.36M+5.9% | $17.59M-22.1% | $19.64M-4.7% | $21.02M+10.1% | $22.05M+25.8% | ||
| —— | —— | —— | —— | —— | ||
| $3.72M+152% | $5.77M+1,244% | $3.21M+271% | $3.36M— | $1.47M— | ||
| $23.54M+6,474% | $10.98M-1.9% | $9.58M-32.2% | $9.5M+8.0% | $358K+344% | ||
| $1.19M+3.6% | $1.18M+2.3% | $1.16M-2.1% | $1.15M-5.7% | $1.15M-8.7% | ||
| -$1.25M-3.1% | -$1.24M-7.1% | -$1.24M-10.4% | -$1.23M-8.7% | -$1.21M-3.9% | ||
| —— | -$6.29M+23.0% | -$6.76M— | -$7.23M— | -$7.7M— | ||
| -$148.72M-19.1% | -$146.72M-40.6% | -$134.67M-39.5% | -$127.16M-37.8% | -$124.83M-43.8% | ||
| —— | —— | —— | —— | -$118.47M-89.9% | ||
| $16.59M+1,580% | $8.39M+402% | $1.1M-14.6% | $1.15M-44.2% | $987K-70.4% | ||
| —— | —— | —— | —— | —— | ||
| $256.78M-1.3% | $211.3M-21.4% | $242.05M+867% | $242.1M+55.6% | $260.22M+83.2% | ||
| —— | —— | —— | —— | $16.92M— | ||
| —— | -$6.29M+23.0% | -$6.76M— | -$7.23M— | -$7.7M— | ||
| -$1.25M-3.1% | -$1.24M-7.1% | -$1.24M-10.4% | -$1.23M-8.7% | -$1.21M-3.9% | ||
| $23.54M+6,474% | $10.98M-1.9% | $9.58M-32.2% | $9.5M+8.0% | $358K+344% | ||
| $5.28M+105% | $6.15M+108% | $6.02M— | $2.27M— | $2.58M— | ||
| $3.72M+152% | $5.77M+1,244% | $3.21M+271% | $3.36M— | $1.47M— | ||
| —— | —— | $6.76M-23.3% | $7.44M-8.1% | $7.92M+13.0% | ||
| $1.19M+3.6% | $1.18M+2.3% | $1.16M-2.1% | $1.15M-5.7% | $1.15M-8.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $205.39M— | —— | —— | —— | ||
| -$1.25M-3.1% | -$1.24M-7.1% | -$1.24M-10.4% | -$1.23M-8.7% | -$1.21M-3.9% | ||
| —— | -$95K+71.8% | -$155.5K— | -$216K— | -$276.5K— | ||
| —— | $177K-76.3% | $319.75K— | $462.5K— | $605.25K— | ||
| —— | $578K-91.1% | $2.06M— | $3.54M— | $5.02M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Olema Pharmaceuticals, Inc. generate?
- Olema Pharmaceuticals, Inc. (OLMA) generated -$148.7M in operating cash flow over the trailing twelve months.
- What is Olema Pharmaceuticals, Inc.'s free cash flow?
- After $332.0K of capital expenditures, Olema Pharmaceuticals, Inc.'s free cash flow was -$115.4M over the trailing twelve months, down 30.9% year over year.
- Where does Olema Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Olema Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.